Ag85B-卡介苗重组疫苗对结核病预防及治疗效果研究

目的评价Ag85B-卡介苗重组疫苗对结核病的预防及治疗效果。方法将小鼠随机分为6组,A、B、C为预防组,D、E、F为治疗组,A、D组为Ag85B-卡介苗重组疫苗免疫组,B、E组为BCG免疫组,C、F组为生理盐水对照组。通过研究各组小鼠在实验中的血清抗体水平、细胞免疫功能等指标以及体重变化、半数死亡时间、2个月死亡率、大体病变等,评价Ag85B-卡介苗重组疫苗在小鼠结核分枝杆菌感染的预防及治疗成效。结果在注射结核分枝杆菌后,各组小鼠体重平均增长明显减慢,C、F组增长最慢。A、B、D、E组与C、F组相比能延长半数死亡时间,降低一定时间内的死亡率。小鼠脏器大体病变各组之间无显著差别。A、B、D、E 4组小鼠,肺脏的结核分枝杆菌生长培养最低稀释度集中在105,肝脏、脾脏结核分枝杆菌生长培养最低稀释度集中在104。C、F组小鼠,肺脏结核分枝杆菌生长的培养最低稀释度集中在106,肝脏、脾脏结核分枝杆菌生长的培养最低稀释度集中在105。各组间的抗体检测及淋巴细胞增殖实验结果无显著差别。结论 Ag85B-卡介苗重组疫苗与卡介苗对于结核分枝杆菌感染的预防作用无显著区别,Ag85B-卡介苗重组疫苗和卡介苗对结核病无明显的治疗效果。

Preventive and therapeatic effect of Ag85B-recombinant BCG vaccine against M.Tuberculosis

Objective To evaluate the prevention and therapeatic effect of Ag85B-recombinant BCG vaccine against M. tuberculosis. Methods The mice were randomly divided into 6 groups. Group A, B, C were prevention groups. Group D, E, F were treatment groups. Group A and D were immunized with Ag85B- recombinant BCG vaccine; Group B and E were immunized with BCG; and Group C and F were injected with physiological saline. A series of indexes such as the serum antibody level, the immune function of T cell and B cell, median weight changes, the half death time of experimental animal, the death rate in 2 month, gross lesions of organs were observed to evaluate the protective effects of Ag85B-recombinant BCG vaccine against M.tuberculosis. Results After being attacked by M.tuberculosis, the growth rate of average weight of mice in each group was slower, physiological saline control group was the slowest. Contrasted with group C and F, Group A, B, D and E could prolong the half death time and reduce the death rate in 2 month. There was no significant difference between groups in gross lesions of organs. The organ culture result indicated that the dilution of 105was the minimum concentration for lung culture in group A, B, D and E, that M.tuberculosis could grow, however, the dilution of 104was the minimun concentration for liver and spleen culture. As to group C and F, the minimum dilution of lung culture that M.tuberculosis could grow in 106, however the minimum dilution of liver and spleen were mainly focused on 105. The experimental results of antibody and lymphocyte proliferation in each group had no significant difference. Conclusion Ag85B- recombinant BCG vaccine couldn＇t improve protection effect of BCG. Recombinant BCG vaccine or BCG did not show apparent prevention of M. Tuberculosis infection.